Long-term Non-interventional Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

  • End date
    Dec 23, 2034
  • participants needed
  • sponsor
    Fate Therapeutics
Updated on 23 January 2021


Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.


This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months ( one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Condition Pancreatic Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Adenocarcinoma, Colorectal Cancer, Disorders of cervix NOS, Microsatellite Instability, Malignant neoplasm of kidney, Rectal disorder, Neuroendocrine carcinoma, Uterine Cancer, Lymphoma, Carcinoma, melanoma, Squamous cell carcinoma, Transitional cell carcinoma, Renal Cell Carcinoma, skin cancer, HEPATIC NEOPLASM, Lymphoproliferative Disorder, Lymphoma, Small Cell Lung Cancer, HEPATOCELLULAR CARCINOMA, Gastropathy, Gastric Cancer, Merkel cell carcinoma, head and neck cancer, Stomach Discomfort, Metastatic Melanoma, Vulvar Dysplasia and Carcinoma, Non-Hodgkin's Lymphoma, Colon Cancer Screening, Rectal Disorders, Colon cancer; rectal cancer, Advanced Solid Tumor, HER2 Positive Breast Cancer, Gastric Carcinoma, Advanced Malignancies, Islet Ce417ll Cancer, EGFR Positive Solid Tumor, Advanced Malignant Solid Tumor, Kidney Cancer, Malignant Melanoma, Liver Cancer, Malignant Adenoma, Stomach Cancer, Renal Cell Cancer, Renal Cancer, Lymphoproliferative disorders, Urothelial Carcinoma, cervical carcinoma, clear cell renal cell carcinoma, colorectal neoplasm, gastric cancers, her2/neu-positive breast cancer, her2-positive breast cancer, colorectal cancers, lymphomas, nsclc, cancer of the head and neck, cervical cancer, uterine, cancer of the pancreas, carcinoma of the cervix uteri, carcinoma of the cervix, cervix cancer, cancer of the cervix, carcinoma of cervix, epidermoid carcinoma, squamous cell cancer, pancreatic cancers, cancer, pancreatic, liver cell carcinoma, cancer, colorectal, colorectal tumor, tumors, colorectal, sclc, small cell carcinoma, small cell carcinoma of the lung
Treatment Allogeneic natural killer (NK) cell
Clinical Study IdentifierNCT04106167
SponsorFate Therapeutics
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Advanced Malignancies or Lymphoma or carcinoma of cervix or Advanced Malignant Solid Tumor or Colon cancer; rectal cancer or squamous cell cancer or G...?
Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
Subjects who have provided Informed consent prior to their study participation

Exclusion Criteria

Not Applicable
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note